Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02118, USA.
Hematol Oncol Clin North Am. 2011 Apr;25(2):393-413, ix. doi: 10.1016/j.hoc.2011.02.002.
Alloimmunity in pregnancy is the basis for two of the major complications of pregnancy in transfusion medicine: hemolytic disease of the fetus and newborn (HDFN), and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Use of Rh(D) immune globulin has dramatically reduced the incidence of HDFN in Rh(D)-mismatched pregnancies. Treatment of HDFN may involve intrauterine transfusion, with fetal and neonatal survival rates of 70% to 90%. Treatments for FNAIT include immune globulin, steroids, or in severe cases, intrauterine platelet transfusions. Transfusion medicine is central to the management of pregnancy-associated complications such as postpartum hemorrhage, parvovirus B19 infection, hemoglobinopathies, and aplastic anemia.
胎儿和新生儿溶血病（HDFN）和胎儿及新生儿同种免疫性血小板减少症（FNAIT）。Rh（D）免疫球蛋白的应用显著降低了 Rh（D）不相容妊娠中 HDFN 的发生率。HDFN 的治疗可能包括宫内输血，胎儿和新生儿的存活率为 70%至 90%。FNAIT 的治疗包括免疫球蛋白、类固醇，或在严重情况下，宫内血小板输注。输血医学是处理与妊娠相关并发症（如产后出血、细小病毒 B19 感染、血红蛋白病和再生障碍性贫血）的核心。
